Log in
NASDAQ:XOMA

XOMA Stock Forecast, Price & News

$32.05
-0.61 (-1.87 %)
(As of 11/27/2020 12:00 AM ET)
Add
Compare
Today's Range
$31.84
Now: $32.05
$33.19
50-Day Range
$19.58
MA: $25.47
$33.03
52-Week Range
$14.14
Now: $32.05
$34.00
Volume10,431 shs
Average Volume48,161 shs
Market Capitalization$353.26 million
P/E RatioN/A
Dividend YieldN/A
Beta1.26
XOMA Corporation, a biotech royalty aggregator, discovers and develops therapeutic candidates in the United States, Europe, and the Asia Pacific. The company has a pipeline of monoclonal antibodies and technologies to license to pharmaceutical and biotechnology companies to further their clinical development. Its proprietary product candidates include X213, an allosteric inhibitor of prolactin action; XMetA, an insulin receptor-activating antibody to provide long-acting reduction of hyperglycemia in Type 2 diabetic patients; IL-2, a therapy for metastatic melanoma and renal cell carcinoma; and PTH1R program, an anti-parathyroid receptor pipeline to address unmet medical needs, including primary hyperparathyroidism and humoral hypercalcemia of malignancy. The company also licenses antibody discovery, optimization, and development technologies. It has research and development collaboration agreements with Novartis Vaccines and Diagnostics, Inc.; Novartis Pharma AG; Novartis International Pharmaceutical Ltd.; Rezolute, Inc.; and Takeda Pharmaceutical Company Limited. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.
Read More
XOMA logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.43 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:XOMA
CUSIP98419J10
Phone510-204-7200
Employees11

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$18.37 million
Book Value$5.03 per share

Profitability

Net Income$-1,980,000.00
Net Margins-102.23%

Miscellaneous

Market Cap$353.26 million
Next Earnings Date3/9/2021 (Estimated)
OptionableNot Optionable
$32.05
-0.61 (-1.87 %)
(As of 11/27/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive XOMA News and Ratings via Email

Sign-up to receive the latest news and ratings for XOMA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











XOMA (NASDAQ:XOMA) Frequently Asked Questions

How has XOMA's stock price been impacted by COVID-19?

XOMA's stock was trading at $19.50 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, XOMA shares have increased by 64.4% and is now trading at $32.05.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of XOMA?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for XOMA in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for XOMA
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than XOMA?

Wall Street analysts have given XOMA a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but XOMA wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is XOMA's next earnings date?

XOMA is scheduled to release its next quarterly earnings announcement on Tuesday, March 9th 2021.
View our earnings forecast for XOMA
.

How were XOMA's earnings last quarter?

XOMA Co. (NASDAQ:XOMA) announced its quarterly earnings data on Thursday, November, 5th. The biotechnology company reported ($0.10) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.21) by $0.11. The biotechnology company earned $0.56 million during the quarter, compared to the consensus estimate of $2.30 million. XOMA had a negative return on equity of 28.83% and a negative net margin of 102.23%.
View XOMA's earnings history
.

What price target have analysts set for XOMA?

2 brokerages have issued 1 year price objectives for XOMA's shares. Their forecasts range from $30.00 to $36.00. On average, they anticipate XOMA's share price to reach $33.00 in the next year. This suggests a possible upside of 3.0% from the stock's current price.
View analysts' price targets for XOMA
.

Who are some of XOMA's key competitors?

What other stocks do shareholders of XOMA own?

Who are XOMA's key executives?

XOMA's management team includes the following people:
  • Mr. James R. Neal, CEO & Director (Age 64, Pay $798.65k)
  • Mr. Thomas M. Burns, Sr. VP of Fin. & CFO (Age 46, Pay $552.2k)
  • Mr. Danny J. Hart Jr., VP & Gen. Counsel (Age 44)

What is XOMA's stock symbol?

XOMA trades on the NASDAQ under the ticker symbol "XOMA."

Who are XOMA's major shareholders?

XOMA's stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (4.09%), State Street Corp (0.62%), WINTON GROUP Ltd (0.17%), Charles Schwab Investment Management Inc. (0.14%), Alps Advisors Inc. (0.13%) and JPMorgan Chase & Co. (0.02%). Company insiders that own XOMA stock include Bvf Partners L P/Il, James R Neal, Ness W Denman Van, Thomas M Burns and Value Fund L P Biotechnology.
View institutional ownership trends for XOMA
.

Which institutional investors are selling XOMA stock?

XOMA stock was sold by a variety of institutional investors in the last quarter, including WINTON GROUP Ltd, Morgan Stanley, Charles Schwab Investment Management Inc., Alps Advisors Inc., and JPMorgan Chase & Co.. Company insiders that have sold XOMA company stock in the last year include James R Neal, and Thomas M Burns.
View insider buying and selling activity for XOMA
.

Which institutional investors are buying XOMA stock?

XOMA stock was acquired by a variety of institutional investors in the last quarter, including State Street Corp, and BlackRock Inc.. Company insiders that have bought XOMA stock in the last two years include Bvf Partners L P/Il, James R Neal, and Value Fund L P Biotechnology.
View insider buying and selling activity for XOMA
.

How do I buy shares of XOMA?

Shares of XOMA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is XOMA's stock price today?

One share of XOMA stock can currently be purchased for approximately $32.05.

How big of a company is XOMA?

XOMA has a market capitalization of $353.26 million and generates $18.37 million in revenue each year. The biotechnology company earns $-1,980,000.00 in net income (profit) each year or ($0.23) on an earnings per share basis. XOMA employs 11 workers across the globe.

What is XOMA's official website?

The official website for XOMA is www.xoma.com.

How can I contact XOMA?

XOMA's mailing address is 2200 POWELL STREET SUITE 310, EMERYVILLE CA, 94608. The biotechnology company can be reached via phone at 510-204-7200 or via email at [email protected]

This page was last updated on 11/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.